Multiple studies show Nu.Q® NETs test could predict sepsis patients at risk of deteriorating
VolitionRx (NYSE AMERICAN: VNRX) has published findings from three large, independent studies conducted in France, Germany, and the Netherlands, involving over 3,000 sepsis patients. The studies demonstrate that their Nu.Q® NETs test could predict patients at higher risk of deteriorating from sepsis by measuring levels of circulating H3.1 nucleosomes in the bloodstream. Research shows that elevated H3.1 levels are associated with increased risk of mortality, renal failure, respiratory failure, multi-organ failure, and septic shock. The company is currently seeking to commercialize Nu.Q® NETs and using these study findings to support licensing discussions with industry stakeholders.
VolitionRx (NYSE AMERICAN: VNRX) ha pubblicato i risultati di tre ampi studi indipendenti condotti in Francia, Germania e Paesi Bassi, coinvolgendo oltre 3.000 pazienti affetti da sepsi. Gli studi dimostrano che il loro test Nu.Q® NETs potrebbe prevedere i pazienti a maggior rischio di deterioramento a causa della sepsi misurando i livelli di nucleosomi H3.1 circolanti nel flusso sanguigno. La ricerca mostra che livelli elevati di H3.1 sono associati a un aumentato rischio di mortalità, insufficienza renale, insufficienza respiratoria, insufficienza multiorgano e shock settico. L'azienda sta attualmente cercando di commercializzare Nu.Q® NETs e utilizzare i risultati di questi studi per supportare le discussioni di licenza con i portatori d'interesse del settore.
VolitionRx (NYSE AMERICAN: VNRX) ha publicado los resultados de tres grandes estudios independientes llevados a cabo en Francia, Alemania y los Países Bajos, que involucraron a más de 3,000 pacientes con sepsis. Los estudios demuestran que su prueba Nu.Q® NETs podría predecir a los pacientes con mayor riesgo de deterioro por sepsis al medir los niveles de nucleosomas H3.1 circulantes en el torrente sanguíneo. La investigación muestra que niveles elevados de H3.1 están asociados con un mayor riesgo de mortalidad, insuficiencia renal, insuficiencia respiratoria, falla multiorgánica y shock séptico. La empresa está actualmente buscando comercializar Nu.Q® NETs y utilizar los hallazgos de este estudio para respaldar las discusiones de licencias con interesados de la industria.
VolitionRx (NYSE AMERICAN: VNRX)는 프랑스, 독일 및 네덜란드에서 실시된 세 가지 대규모 독립 연구의 결과를 발표했으며, 3,000명 이상의 패혈증 환자가 포함되었습니다. 연구 결과, 그들의 Nu.Q® NETs 테스트는 혈액 내 순환 H3.1 뉴클레오좀이 높은 환자들이 패혈증으로 악화될 위험이 더 크다는 것을 예측할 수 있음을 보여줍니다. 연구에 따르면, H3.1 수치 상승은 사망 위험, 신부전, 호흡 부전, 다발성 장기 부전 및 패혈성 쇼크와 연관되어 있습니다. 회사는 현재 Nu.Q® NETs의 상용화를 모색하고 있으며, 이러한 연구 결과를 산업 이해관계자와의 라이선스 논의를 지원하는 데 사용하고 있습니다.
VolitionRx (NYSE AMERICAN: VNRX) a publié les résultats de trois grandes études indépendantes menées en France, en Allemagne et aux Pays-Bas, impliquant plus de 3 000 patients atteints de sepsis. Les études montrent que leur test Nu.Q® NETs pourrait prédire les patients à risque accru de détérioration en raison de la sepsis en mesurant les niveaux de nucléosomes H3.1 circulants dans le sang. La recherche montre que des niveaux élevés de H3.1 sont associés à un risque accru de mortalité, d'insuffisance rénale, d'insuffisance respiratoire, d'insuffisance multiviscérale et de choc septique. L'entreprise cherche actuellement à commercialiser Nu.Q® NETs et utilise ces résultats d'étude pour soutenir les discussions de licence avec les parties prenantes du secteur.
VolitionRx (NYSE AMERICAN: VNRX) hat Ergebnisse aus drei großen, unabhängigen Studien veröffentlicht, die in Frankreich, Deutschland und den Niederlanden durchgeführt wurden und über 3.000 Patienten mit Sepsis umfassten. Die Studien zeigen, dass ihr Nu.Q® NETs-Test Patienten mit einem höheren Risiko einer Verschlechterung aufgrund von Sepsis vorhersagen kann, indem die Werte zirkulierender H3.1-Nukleosomen im Blutstrom gemessen werden. Die Forschung zeigt, dass erhöhte H3.1-Werte mit einem erhöhten Risiko für Mortalität, Nierenversagen, Atemversagen, multiorganversagen und septischem Schock assoziiert sind. Das Unternehmen bemüht sich derzeit um die Kommerzialisierung von Nu.Q® NETs und nutzt diese Studienergebnisse zur Unterstützung von Lizenzgesprächen mit Branchenakteuren.
- Three large-scale studies validate Nu.Q® NETs test effectiveness in predicting sepsis deterioration
- Test could enable earlier medical intervention in high-risk sepsis patients
- Technology demonstrates potential for commercialization and licensing opportunities
- Product not yet commercialized
- Still in licensing discussion phase without confirmed partnerships
Insights
Three large-scale independent studies across European centers of excellence demonstrate that Volition's Nu.Q® NETs test effectively predicts sepsis deterioration risk by measuring H3.1 nucleosome levels. This validation from over 3,000 patients significantly strengthens the test's clinical credibility and market potential.
The test's ability to identify patients at risk of serious complications (mortality, organ failure, septic shock) positions it as a valuable early warning system in critical care. This could transform sepsis management protocols and create substantial market opportunities in the $27 billion global sepsis diagnostics market.
While the commercial pathway requires regulatory approvals and market penetration strategy, the strong clinical evidence and the test's reported advantages (simple, low-cost, accessible) suggest promising revenue potential. The ongoing licensing discussions with industry stakeholders could lead to significant partnership opportunities.
The development represents a significant market opportunity in critical care diagnostics. Current sepsis detection methods are often slow or imprecise, creating a clear market gap for rapid, predictive tools. The Nu.Q® NETs test's ability to provide early risk assessment could drive strong adoption in intensive care units globally.
The test's commercial prospects are enhanced by its potential to reduce healthcare costs through earlier intervention and improved patient outcomes. With sepsis being a leading cause of hospital deaths and carrying high treatment costs, healthcare providers have strong economic incentives to adopt predictive tools that can optimize resource allocation and improve survival rates.
The symposium explored research findings from three large, independent studies carried out at centers of excellence in
Professor Djillali Annane, Professor of Medicine at University Paris Saclay-UVSQ and Chair of Volition's ESICM Lives symposium said:
"The findings of these studies, summarized in Volition's report, clearly and consistently show that an elevated level of circulating H3.1 nucleosomes in sepsis patients reflects a dysregulated immune response and is associated with an increased risk of mortality, renal failure, respiratory failure, multi-organ failure, and septic shock.
"As a physician, we now know that sepsis patients, with an elevated H3.1 level on admission to intensive care, are at greater risk of deteriorating and we need to act quickly.
"I believe that using the Nu.Q® NETs test to measure elevated H3.1 nucleosome levels as a "treatable trait" in sepsis management could be a game changer in modifying a patient's trajectory. Introducing Nu.Q® NETs into hospitals could lead to new ways of treating sepsis, improve patient survival and the quality of life of survivors."
Dr Andrew Retter, Chief Medical Officer at Volition, added:
"Nu.Q® NETs, Volition's nucleosome quantification technology, is a simple, low-cost, accessible test to detect diseases associated with NETosis. Although NETs play a critical role in our normal immune response, elevated levels of NETs can lead to tissue damage and in severe cases, sepsis, organ failure, and death.
"Being able to predict a sepsis patient's clinical course early, by using Nu.Q® NETs in clinical practice, could significantly enhance sepsis management, enabling physicians more time to intervene and improve patient outcomes."
Volition is currently seeking to commercialize Nu.Q® NETs and the findings from these latest studies, highlighted in the company's ESICM symposium report, will support ongoing licensing discussions with key industry stakeholders.
Download Volition's report, titled: 'Sepsis: a brighter hope for tomorrow' here.
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life. For more information about Volition's technology go to: www.volition.com.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition, mediarelations@volition.com +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, the potential uses, benefits and effectiveness of Volition's Nu.Q® technology platform. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this press release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™, Capture-PCR™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
View original content:https://www.prnewswire.com/news-releases/multiple-studies-show-nuq-nets-test-could-predict-sepsis-patients-at-risk-of-deteriorating-302292798.html
SOURCE VolitionRx Limited
FAQ
What did the recent studies reveal about VolitionRx's (VNRX) Nu.Q® NETs test?
How many patients were involved in VolitionRx's (VNRX) sepsis studies?
What is the current commercialization status of VolitionRx's (VNRX) Nu.Q® NETs test?
